Overall, our data support a role for STYK1 in drug tolerance to EGFR TKI, making it a potential candidate target for increasing the sensitivity of EGFR mutant NSCLC cells to EGFR inhibition and preventing the emergence of drug tolerant cells. Here, EGFR is linked to non-small cell lung carcinoma.